FBIO Fortress Biotech, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1429260 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.3%
TTM net income YoY2,411.2%
TTM EPS YoY2,016.7%
Revenue 3-yr CAGR-4.7%
Net income 3-yr CAGR—
Margins
Gross margin66.2%
Operating margin-42.5%
Net margin143.0%
FCF margin—
EBITDA margin-41.9%
Returns
ROE92.8%
ROA43.4%
ROIC (approx.)-227.3%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets36.8%
Debt / equity0.00x
Current ratio2.93x
Interest coverage-3.17x
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.16M | $18.72M | $16.04M | $16.08M | $17.63M | $16.41M | $13.14M | $15.12M |
| Cost of revenue | $5.88M | $6.14M | $6.22M | $5.44M | $5.75M | $4.94M | $4.79M | $2.24M |
| Gross profit | $13.28M | $12.57M | $9.82M | $10.64M | $11.88M | $11.47M | $8.35M | $12.88M |
| R&D expense | $1.68M | $805,000 | $540,000 | -$367,000 | $208,000 | $8.13M | $3.94M | $9.69M |
| SG&A expense | $17.82M | $20.81M | $15.89M | $14.73M | $17.41M | $38.76M | $25.66M | $26.86M |
| Operating income | -$7.19M | -$10.01M | -$7.74M | -$4.79M | -$6.81M | -$36.47M | -$22.32M | -$23.84M |
| Interest expense | $2.50M | $1.48M | $3.37M | $2.04M | $2.74M | $2.52M | $2.81M | $2.59M |
| Pretax income | -$8.31M | $922,000 | $142.29M | -$6.21M | $8.85M | -$11.65M | -$24.69M | -$25.98M |
| Income tax | -$56,000 | $320,000 | $5.13M | -$816,000 | $26,000 | $0 | $0 | $336,000 |
| Net income | -$5.84M | -$468,000 | $110.37M | -$3.94M | $5.85M | $15.49M | -$10.58M | -$6.76M |
| EBITDA | -$7.09M | -$9.91M | -$7.65M | -$4.70M | -$6.71M | -$36.37M | -$22.19M | -$23.69M |
| EPS (basic) | -0.23 | -0.08 | 3.44 | — | 0.13 | 0.50 | -0.48 | — |
| EPS (diluted) | -0.23 | -0.08 | 2.82 | — | 0.11 | 0.45 | -0.48 | — |
| Weighted avg. shares (diluted) | 33.75M | 31.79M | 38.41M | — | 33.10M | 29.82M | 26.45M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $152.19M | $196.58M | $255.84M | $79.38M | $86.22M | $74.39M | $91.34M | $58.81M |
| Receivables | $47.39M | $36.25M | $24.99M | $29.78M | $17.98M | $15.64M | $18.02M | $10.23M |
| Inventory | $7.77M | $8.16M | $9.29M | $9.62M | $11.82M | $12.85M | $12.50M | $14.43M |
| Current assets | $210.36M | $245.51M | $295.48M | $123.84M | $118.50M | $110.40M | $126.90M | $90.37M |
| PP&E, net | $2.32M | $2.41M | $2.43M | $2.52M | $2.61M | $2.70M | $2.80M | $3.26M |
| Intangibles | $24.54M | $25.51M | $26.48M | $27.61M | $28.67M | $29.73M | $30.80M | $31.86M |
| Total assets | $280.21M | $316.71M | $356.87M | $185.55M | $181.41M | $159.90M | $178.07M | $144.22M |
| Current liabilities | $71.76M | $62.02M | $103.39M | $49.74M | $54.07M | $57.52M | $73.67M | $71.40M |
| Long-term debt | — | $35.00M | $37.50M | $54.49M | $47.77M | $50.03M | $56.38M | $57.96M |
| Total debt | — | $35.00M | $37.50M | $54.49M | $47.77M | $50.03M | $56.38M | $57.96M |
| Total liabilities | $103.19M | $110.63M | $154.50M | $123.36M | $116.22M | $122.51M | $145.59M | $145.87M |
| Shareholders' equity | $160.00M | $164.14M | $162.21M | $49.87M | $55.86M | $43.92M | $22.25M | $22.74M |
| Net debt | — | -$161.58M | -$218.34M | -$24.89M | -$38.44M | -$24.36M | -$34.96M | -$853,000 |
| Shares outstanding | 33.49M | 33.31M | 33.19M | 31.36M | 31.01M | 29.75M | 29.55M | 27.91M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.20M | -$59.28M | $203.85M | -$12.54M | -$6.11M | -$27.56M | -$19.56M | -$12.91M |
| Capital expenditure | $7,000 | — | — | — | — | — | — | $0 |
| Free cash flow | -$6.20M | — | — | — | — | — | — | -$12.91M |
| Investing cash flow | -$7,000 | -$79,000 | $0 | $0 | $2.87M | $6.09M | $1.17M | -$15.00M |
| Financing cash flow | -$38.19M | $91,000 | -$27.39M | $5.71M | $15.07M | $4.52M | $52.14M | $25.81M |
| Depreciation & amortization | $100,000 | $100,000 | $93,000 | $92,000 | $100,000 | $100,000 | $126,000 | $144,000 |
| Stock-based compensation | $2.15M | $2.88M | $1.76M | $2.46M | $3.20M | $16.79M | $6.29M | $16.19M |
| Dividends paid | — | — | $0 | $166,000 | $166,000 | $166,000 | $166,000 | $166,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.